A study found that 2% of patients taking dupilumab for atopic dermatitis (AD) are likely to experience conjunctivitis, with occurrences happening most frequently within the first 16 weeks of therapy. Developed for AD treatment, dupilumab inhibits signaling of interleukin (IL)-4 and IL-13, found in inflammatory diseases like AD, asthma, and others. In a study of trials evaluating dupilumab, adverse effects were assessed, with conjunctivitis rates appearing higher in patients receiving dupilumab. The study suggested that clinically meaningful conjunctivitis occurred frequently in the first 16 weeks of treatment, affecting about 2% of those treated, especially those with severe AD and atopic comorbidities.
Source link
How Common Is It in Patients on Dupilumab?
